Table 4.
Bone Resorption Parameters After 2 and 12 Months of Romosozumab
| Month 2 | Month 12 | |||||
|---|---|---|---|---|---|---|
| Romosozumab | Romosozumab | |||||
| Placebo | 210 mg QM | Placebo | 210 mg QM | |||
| N = 14 | N = 15 | p value a | N = 31 | N = 39 | p value a | |
| Cancellous bone | ||||||
| Cn‐ES/BS | 3.4 | 1.8 | 0.022 | 2.9 | 1.1 | <0.001 |
| % | (1.9, 4.5) | (0.9, 3.2) | (2.0, 4.5) | (0.5, 1.7) | ||
| Cn‐Oc.S/BS | 0.1 | 0.0 | 0.032 | 0.1 | 0.0 | 0.001 |
| % | (0.04, 0.2) | (0.0, 0.1) | (0.0, 0.3) | (0.0, 0.03) | ||
| Cn‐Oc.N/BS | 2.4 | 0.0 | 0.024 | 2.0 | 0.0 | <0.001 |
| /100 mm | (1.0, 5.6) | (0.0, 2.4) | (0.0, 6.5) | (0.0, 1.4) | ||
| Endocortical bone | ||||||
| Ec‐ES/BS | 6.3 | 1.6 | 0.003 | 4.1 | 0.5 | <0.001 |
| % | (3.3, 7.7) | (0.6, 3.5) | (3.0, 6.5) | (0.2, 1.2) | ||
| Ec‐Oc.S/BS | 0.2 | 0.0 | 0.12 | 0.0 b | 0.0 b | <0.001 |
| % | (0.0, 0.3) | (0.0, 0.1) | (0.0, 0.4) | (0.0, 0.0) | ||
| Ec‐Oc.N/BS | 4.4 | 0.0 | 0.14 | 0.0 c | 0.0 c | 0.001 |
| /100 mm | (0.0, 7.7) | (0.0, 4.8) | (0.0, 8.4) | (0.0, 0.0) | ||
Values are median (Q1, Q3) unless otherwise specified.
Cn = cancellous; Ec = endocortical; ES/BS = eroded surface per unit of bone surface; Oc.N/BS = osteoclast number per unit of bone surface; Oc.S/BS = osteoclast surface per unit of bone surface; Q1, Q3 = quartiles 1 and 3; QM = once monthly.
a
the Wilcoxon rank sum test.
b
Mean ± SD: 0.3 ± 0.7 in placebo, 0.03 ± 0.09 in romosozumab.
c
Mean ± SD: 8.1 ± 16.2 in placebo, 1.0 ± 2.9 in romosozumab.